Learn More
INTRODUCTION Subjects with autosomal dominant polycystic kidney disease (ADPKD) who were taking tolvaptan experienced aminotransferase elevations more frequently than those on placebo in the TEMPO 3:4 (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) clinical trial. METHODS An independent,(More)
Excretion of catecholamines, DOPA and their oxidoreduction states were studied during aversive conditioning in a 10-sitting experiment in man. Urinary samples in 3 intervals of 8 h. before respective sitting and 20, 80 and 200 minutes after the sitting. The initial unspecific phase of conditioning corresponds to an increase and decrease of catecholamine(More)
BACKGROUND Autosomal dominant polycystic kidney disease (ADPKD) results in kidney cyst development and enlargement, resulting in chronic kidney disease (CKD) leading to renal failure. This study sought to determine if ADPKD patients in the early stages of CKD contribute to a sizable economic burden for the US health care system. METHODS This was a(More)
  • 1